GSK GSK plc Forward P/S Multiple

Corporate company logo of GlaxoSmithKline (GSK)

The GSK plc (GSK) ecosystem is based on preventive therapy and the development of critical vaccines. The issuer's forward P/S confirms the stability of this vector, while 1.30 shows the current value of this metric. Laboratory robotization is accelerating drug screening, while active M&A deals in oncology and strategic partnerships with institutes provide the synergy needed to bring unique medications to market.

GSK GlaxoSmithKline plc: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for gsk.com (GSK)

- current price and projected stock value:
Stock Price GlaxoSmithKline|GSK - Analyst Target Range
- market capitalization data:
Market Capitalization GSK Corp|GSK - Full Takeover Company Value
- issuer book value statistics:
Net Assets per Single Share GSK|GSK - Book Valuation of Business|Market Value to Book Value Ratio gsk.com|GSK - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio GSK plc|GSK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity GlaxoSmithKline|GSK - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio GSK Corp|GSK - Company Long-Term Debt|Company Short-Term Debts GSK|Quick Ratio gsk.com
- business earnings and investment ratios data:
GSK - Annual Net Income|Expected Profit GSK plc|GSK - Business Payback Period|Future Price to Earnings GlaxoSmithKline|GSK - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GSK Corp|GSK - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) GSK|GSK - Earnings per share for the trailing year|Quarterly EPS earnings growth gsk.com|GSK - Earnings growth in current year|Net earnings per share growth forecast for next year GSK plc
- sales volume and revenue indicators:
GSK - Company Sales Revenue|Company Projected Revenue GlaxoSmithKline|GSK - Market Cap to Revenue|Forward P/S Multiple GSK Corp
Fundamental valuation:GSK (GSK Corp)
Manufactured products of GlaxoSmithKline

The reliability of the costly cold chain for GSK plc (GSK) vaccine delivery ensures a steady revenue stream, which is reflected in the trend of the projected market cap-to-revenue ratio. This indicator correlates the company's current market value with expected annual sales to identify the phase of the market cycle. The upward curve confirms market optimism and strengthening fundamentals, allowing investors to timely assess the asset's degree of overboughtness.

Who GSK plc competes with

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|AstraZeneca AB - Forward P/S Multiple|Projected Price to Revenue Novartis Pharma (NVS)|Merck & Co., Inc. (MRK) - Price-to-Projected Revenue Ratio|NVO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Amgen|Forward P/S Multiple Pfizer Inc|Forward Price-to-Revenue Multiple SNY (Sanofi Aventis)|BMY (Bristol-Myers Squibb Co.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Takeda Pharmaceutical TAK|TEVA (tevapharm.com) - Future Price to Revenue|RDY - Price-to-Projected Revenue Ratio|VTRS: Price-to-Projected Revenue Ratio|ROIV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Zai Lab Corp|BHC (Bausch Health Companies) - Forward P/S Multiple|COSM - Projected Price to Revenue